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Abstract
Background: Despite CDC recommendations regarding universal catch-up vaccination against human
papillomavirus (HPV), only about ten percent of young adult women in the United States have been vaccinated.
The purpose of this study was to better understand reasons for non-vaccination among insured 19-26 year-old
women and to evaluate future vaccination intentions.
Methods: We used an administrative claims database from a large US managed care plan to identify women aged
19-26 for receipt of a mailed survey. From a sample of 1,375 women with no evidence of HPV vaccination from
June 1, 2006 through April 30, 2007, 222 completed surveys were received, of which 185 were eligible for this
analysis. The main outcome measures were unvaccinated women’s attitudes and vaccine awareness, likelihood of
future action regarding the vaccine, and reasons for inaction.
Results: Among the 185 non-vaccinees, 25.4% were married, 83.2% were white, and 89.2% had a college or higher
level education. The vaccine was described as very important by 32.4% of subjects, and 30.1% had discussed the
vaccine with a doctor and received a doctor’s recommendation. Half or fewer of respondents were “very” or
“extremely” likely to discuss the vaccine with their doctor (50.0%), do additional research on the vaccine (42.6%),
ask a doctor to get the vaccine (37.5%), or make an appointment to get the vaccine (27.8%), while 48.0% were
“somewhat”, “very”,o r“extremely” likely to do nothing to get the vaccine. Among the latter, reasons for taking no
action included being married or in a monogamous relationship (54.9%), belief that the vaccine is too new (35.4%),
not having enough information about the vaccine (31.7%), concerns about side effects (24.4%), and uncertainty
about insurance coverage (24.4%).
Conclusions: Educational interventions may be needed to enhance HPV vaccination rates among 19-26 year-old
women, particularly regarding information about vaccine safety, vaccine efficacy, insurance coverage, and the value
of vaccination to women in monogamous relationships.
Background
Human papillomavirus (HPV) is the most common
sexually transmitted infection in the United States [1].
Low-risk HPV types 6 and 11 cause 90% of cases of
genital warts, while high-risk HPV types 16 and 18 are
responsible for 70% of cervical cancers and also cause
cancers of the anus, vagina, vulva, and head and neck
[2,3].
Two vaccines have been developed for the prevention
of HPV infection. One is bivalent, targeting high-risk
HPV types 16 and 18 [4], and approved by the FDA in
October, 2009 for the prevention of cervical cancer and
certain precancerous lesions caused by HPV infection
[5]. The quadrivalent vaccine, which targets HPV types
6, 11, 16, and 18 [6,7], was approved by the FDA in
2006 for the prevention of cervical cancer, certain pre-
cancerous lesions, and genital warts in females and, in
2009, for the prevention of genital warts in males [8,9].
In 2007 the CDC’s Advisory Committee on Immuniza-
tion Practices (ACIP) recommended routine vaccination
of 11-12 year-old femalesw i t ht h r e ed o s e so ft h e
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year-old females who have not been vaccinated pre-
viously [10]. Recent, provisional recommendations from
the ACIP extend these recommendations to the bivalent
vaccine and also state that the quadrivalent HPV vaccine
may be given to males aged 9 through 26 years to
reduce their likelihood of acquiring genital warts [11].
Despite the ACIP recommendation, vaccination cover-
age rates remain low (≤36%) [12,13], particularly among
18-26 year-old females (10-12%) [14,15]. Given that
there is demonstrated benefit to immunizing young
adults, even if they are already sexually active [16], it is
important to gain a better understanding of the patient
factors that are associated with vaccination and non-vac-
cination in this age group.
A previous article by the authors using the same data-
base as the present study compared vaccinated with
non-vaccinated women and demonstrated the impor-
tance of a physician’s recommendation to vaccination
decisions [17]. The present analyses were conducted to
explore in greater depth the reasons for limited uptake
of the HPV vaccine among young adult women who
have yet to be vaccinated.
Methods
Study design
Subjects were identified using medical and pharmacy
claims from a large US managed care plan affiliated
with i3 Innovus. The health plan provides fully insured
coverage of physician, hospital, and prescription drug
services to more than 15 million patients across the four
major geographic regions of the United States: the
Northeast, Midwest, South, and West. A self-adminis-
tered survey assessed factors related to an individual’s
decision to receive or not receive HPV vaccine adminis-
tration. One of the authors (MBG) is an employee of i3
Innovus and accessed the claims data to identify patients
who qualified for this study. This research was carried
out in compliance with the Declaration of Helsinki
(http://www.wma.net/en/30publications/10policies/b3/
17c.pdf) and ethics approval for the study was obtained
by the Copernicus Group Independent Review Board
(http://www.copernicusgroup.com).
Patient sample
Women were identified in the health plan database if:
they received a new claim for the HPV vaccine or any
outpatient medical claim during an identification period
defined as January 1 to April 30, 2007; were 19-26 years
of age on the index date (i.e., first date of claim during
identification period); and were continuously enrolled in
the health plan for 6 months prior to and 12 months
following the index date. Women were excluded if they
had a medical claim related to pregnancy, delivery, or
cervical cancer during the identification period. A total
of 611,955 women met the above criteria.
Two samples of 1,375 women were randomly selected
from among women who had: (1) a first HPV vaccine
dose during the identification period, and (2) no doses
of HPV vaccine during the identification period or dur-
ing the 6 months before that period [17]. The second
group (non-vaccinees) constitutes the patient sample for
this analysis. The sample size of 1,375 women per group
(vaccinated, unvaccinated) was chosen to ensure that
the final sample sizes provided adequate power to detect
differences between the two groups for the analyses
reported in the previous publication [17].
Survey administration
Survey packets were mailed beginning in April 2008.
Packets contained an invitation letter, an informed con-
sent form, a 7-page survey assessing factors related to
an individual’s decision to receive or not receive the
HPV vaccine, and a payment of $10 as compensation
for participation. Reminder post-cards were sent one
week following the initial mailing, and a second survey
packet was sent to non-respondents after three weeks.
The total survey collection period was 8 weeks.
Survey content
The survey collected standard demographic and health
status information (Additional file 1: HPV vaccine ques-
tionnaire 18-26). Questions addressed attitudes toward
reproductive health, vaccine awareness, and discussion
of the vaccine with a physician. Non-vaccinees were
asked about the likelihood of receiving the vaccine in
the future.
To assess attitudes toward reproductive health respon-
dents were asked to rate their level of agreement, from
1 (strongly disagree) to 6 (strongly agree), with state-
ments such as “Cervical cancer is a devastating disease,”
“Genital warts are an embarrassing condition,” and
“I am comfortable discussing sexual health issues with a
doctor or nurse.”
To assess vaccine awareness, respondents were first
asked if they had ever heard of a vaccine to help prevent
cervical cancer or HPV infection. If yes, they were then
asked a series of questions about their perception of the
personal importance of the HPV vaccine by the ques-
tion, “How important do you think the vaccine to help
prevent cervical cancer is for you?” Possible answers
were ‘not at all important’, ‘not very important’, ‘some-
what important’, and ‘very important’.
The questions that addressed discussion with and
recommendation by a physician were: “Have you dis-
cussed the vaccine to help prevent cervical cancer with
ad o c t o r ? ” and “Did a doctor recommend that you get
the vaccine to help prevent cervical cancer?” If the
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vaccine, she was asked, “How strongly did the doctor
recommend you get the cervical cancer vaccine on a
scale from 1 to 5?” Ar a t i n go f1c o r r e s p o n d e dt ot h e
response that ‘a doctor did not strongly recommend the
vaccine’ and a rating of 5 meant that ‘a doctor strongly
recommended the vaccine’.
The likelihood of taking additional action regarding
the HPV vaccine was assessed via the question, “If you
have not received a single dose of the cervical cancer
vaccine, in the future how likely are you to” followed
by 5 choices: ‘Ask a doctor to get this vaccine?’,
‘Do additional research on this vaccine?’, ‘Discuss the
vaccine with a doctor?’, ‘Make an appointment to get
the vaccine?’,a n d‘Do nothing to get the vaccine?’.
The answers were measured on a 5-point Likert-type
scale, ranging from ‘n o ta ta l ll i k e l y ’ (1) to ‘extremely
likely’ (5).
Respondents who were somewhat, very, or extremely
likely (3-5 on the Likert-type scale) to ‘do nothing to get
the vaccine’ were asked their reasons for inaction. Possi-
ble answers were ‘I am not sexually active’, ‘The vaccine
is too new’, ‘I am married or in an exclusive (monoga-
mous) relationship’, ‘I am unsure if my insurance would
cover the vaccine cost’, ‘I do not have enough informa-
tion about this vaccine’, ‘I am concerned about the side
effects’, ‘I am pregnant or trying to conceive’, ‘My doctor
recommended against getting the vaccine’, and ‘I cannot
afford the cost of the vaccine’. Respondents were
instructed to ‘check all that apply’ and were given the
option of articulating their own reason(s).
Data analysis
A descriptive analysis was conducted to determine the
attitudes of non-vaccinees toward the HPV vaccine,
their awareness of the vaccine, their interaction with a
physician relating to the vaccine, the likelihood of their
taking future action regarding HPV vaccination, and
their reasons for inaction.
Results
Patient sample
Of the 1,375 surveys sent out to non-vaccinees, 222
were returned complete, for a response rate of 16.1%.
Thirty-seven non-vaccinees were subsequently deter-
mined to be ineligible due to disenrollment or vaccina-
tion after the identification period, leaving 185 surveys
eligible for analysis. As reported in our earlier paper,
there were no differences between respondents and
non-respondents with respect to region of residence or
number of comorbidities [17]. Respondents were statisti-
cally significantly younger (mean age 21.6) than non-
respondents (mean age 22) but this was not a clinically
meaningful difference.
The sociodemographic characteristics and health sta-
tus of the respondents are shown in Table 1. The mean
age (SD) was 22.4 (2.3) years. The majority were not
married (74.6%) and had good,v e r yg o o d ,o re x c e l l e n t
health (92.4%). Most were white (83.2%) and had a col-
lege or higher level education (89.2%).
Attitudes, vaccine awareness, and physician interaction
Most respondents agreed that cervical cancer is a devas-
tating disease (93.5%) and that genital warts are an
embarrassing condition (90.0%), and most reported
being comfortable discussing sexual health issues with a
doctor or nurse (73.0%; Table 2). Of the 185 respon-
dents, 176 reported ever hearing of a vaccine to help
prevent cervical cancer or HPV infection. Of these, less
than one third (32.4%) thought that the HPV vaccine
was very important for them. Likewise, 53 (30.1%)
reported discussing the HPV vaccine with their doctor
and receiving their doctor’s recommendation for the
vaccine. Only 15.3% of all respondents received a
‘strong’ recommendation, while of the 53 women that
received a doctor’s recommendation, 27 (50.9%) received
a strong recommendation.
Likelihood of taking additional action
Most respondents reported being at least somewhat
likely to discuss the HPV vaccine with a doctor in the
Table 1 Respondent characteristics*
N%
Marital Status
Not married 138 74.6
Married 47 25.4
Overall health status
Poor/Fair 14 7.7
Good 50 27.3
Very good 77 42.1
Excellent 42 23.0
Education
High school or less 20 10.8
Some college, or but no degree 82 44.3
Two year degree or college graduate 66 35.7
Graduate school 17 9.2
Race/Ethnicity
White, non-Hispanic 154 83.2
Black, non-Hispanic 5 2.7
Hispanic 14 7.6
Other 12 6.5
Employment status
Full-time 96 51.9
Student status
Student 56 30.3
* Mean age (SD): 22.4 (2.3) years; *N = 185
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(75.0%), ask a doctor to vaccinate them (69.9%), or to
make an appointment to be vaccinated (60.2%; Table 3).
Substantially fewer patients were very or extremely likely
to carry out these actions (Table 3).
Reasons for taking no additional action
The reason most commonly given for taking no addi-
tional action regarding HPV vaccination was being mar-
ried or in a monogamous relationship (54.9%; Table 4).
About a third of the respondents thought the vaccine
w a st o on e w( 3 5 . 4 % )o rt h a tt h e yd i dn o th a v ee n o u g h
information about it (31.7%). One fourth (24.4%) were
concerned about the vaccine’s side effects. Some were
unsure of their insurance coverage (24.4%), and a few
were concerned about the cost of the vaccine (14.6%).
Discussion
The implications of this study must be considered in the
context of several limitations. The opinions recorded in
this survey, for example, are not necessarily representa-
tive of those of the entire target population, because of
a potential response bias towards non-compliant
patients. The response rate of 16.1% was rather low and
was lower than that of the vaccinated subgroup (28%)
[17]. In addition, more than 80% of respondents were
white and all study subjects had access to health care
and were insured. The results regarding intent to get
vaccinated, while interesting, may not ultimately reflect
future behavior. For instance, a meta-analytic review of
Theory of Planned Behavior research reported a relative
modest average correlation of 0.47 between intentions
and subsequent health behaviors [18].
Although the majority of unvaccinated respondents in
this study recognized the potential impact of cervical
cancer and genital warts, only about one in three con-
sidered vaccination against HPV to be important to
them. Half of respondents reported being very or extre-
mely likely to discuss the vaccine with a doctor but
almost half (48.1%) were at least somewhat likely to do
nothing to pursue vaccination. The most frequent rea-
son for inaction was being married or in a monogamous
relationship, but other reasons relating to uncertainty
about the vaccine and insurance/cost issues were
common.
These reasons for inaction echo findings of previous
studies, which noted a perceived lack of need, concerns
about the vaccine, and perceived barriers as factors in
the decision not to be vaccinated. A perceived lack of
n e e d ,u s u a l l yd u et os e x u a li n a c t i v i t yo rl o wr i s k ,w a s
found to be a factor in previous population surveys of
this age group [14,15]. Safety of the vaccine was also
raised as an issue in these surveys [14,15]. In a study of
college-age women, those who had decided to forego
vaccination were less sure of the vaccine’ss a f e t ya n d
were less knowledgeable about risk factors, transmission,
and methods of detection of HPV than were women
who had been vaccinated [19].
As in the present study, a relatively small proportion
of women (7%) in the National Immunization Survey
Table 2 Attitudes, vaccine awareness, and physician interaction
Responses N %
Cervical cancer is a devastating disease (% agreement†) 185 173 93.5
Genital warts are an embarrassing condition (% agreement†) 180 162 90.0
I am comfortable discussing sexual health issues with a doctor or nurse (% agreement†) 185 135 73.0
Vaccine to prevent cervical cancer was very important to them ‡ 176 57 32.4
Doctor discussed and recommended vaccine to help prevent cervical cancer 176 53 30.1
Received a strong recommendation§ from doctor to get cervical cancer vaccine 176 27 15.3
†Strongly or moderately agree (5 or 6 on the 6-point Likert scale).
‡Checking “very important” to a question stated as, “How important do you think the vaccine to prevent cervical cancer is for you?” with possible answers of not
at all, not very, somewhat, or very important.
§Equivalent to a score of 4 or 5 on the 5-point Likert scale.
Table 3 Likelihood of taking additional action regarding HPV vaccination
Responses Somewhat, very, or extremely likely Very or extremely likely*
N% N %
Discuss the vaccine with a doctor 176 149 84.7 88 50.0
Do additional research on vaccine 176 132 75.0 75 42.6
Ask a doctor to get vaccine 176 123 69.9 66 37.5
Make an appointment to get the vaccine 176 106 60.2 49 27.8
Do nothing to get the vaccine 175 84 48.0 37 21.1
* ‘Somewhat likely’ response category removed.
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issues [15]. Cost was also a barrier reported by college
women who had chosen not to receive the vaccine [19].
However, larger numbers reported other barriers to vac-
cination, including lack of time or failure to make a doc-
tor’s appointment (21% in the NIS 2007) [15]. Similarly,
in a follow-up study that included women aged 13-26,
45% of young women who had not yet been vaccinated
had simply not returned to the clinic in the six months
since the baseline study [13].
In our previous paper published from this data set we
found that those respondents who reported physician
discussion/recommendation of HPV vaccination were
significantly more likely to be in the vaccinated group
[17]. The women described here remained unvaccinated,
and only 30.1% had received a recommendation from
their physician to be vaccinated, with only 15% receiving
a strong recommendation.
Responses to questions about taking additional action
suggested ambivalence on the part of non-vaccinees
(almost 70% were at least somewhat likely to ask a doc-
tor to get the vaccine, while 48% expressed being at
least somewhat likely to do nothing). This inconsistency
may have resulted from the choice of cutoff ("some-
what,”“ very,” and “extremely” likely) in the accepted
responses. There was no discrepancy if the threshold
was set at “very” or “extremely” likely, when from 27.8%
to 50.0% would take some action regarding the vaccine,
and 27.1% would do nothing. Ambivalence about vacci-
nation is, however, consistent with the lack of correla-
tion between the intention to be vaccinated and actual
vaccination observed in one post-vaccine study [13].
This result may explain the discordance in the United
States between the findings of studies carried out before
the vaccine became available, which showed favorable
attitudes toward HPV vaccination (74-89% acceptance
rate) [20-23], and current low vaccination rates (5-36%)
[12,13]. Alternatively, these low rates of vaccination may
reflect an inefficient method of vaccine delivery for
young adult women in the United States. In countries
with school-based vaccination programs for girls, there
is good agreement between rates of pre-vaccine accep-
tance and actual vaccination. In England, for instance,
more than 80% of people surveyed were in favor of
HPV vaccination [24], and school-based programs have
reported more than 70% uptake of the first vaccine dose
among 12-13 year-olds [25,26]. In Australia, the pre-vac-
cine acceptance rate was about 80% [27]. When a
school-based program in Queensland contracted with a
general practice to provide recommended immuniza-
tions, uptake of all three doses of the HPV vaccine was
79% [28].
Conclusions
These findings suggest that educational interventions
may be necessary to enhance HPV vaccination rates
among young adult women. Although some of these
women currently may be at low risk for infection, using
assessment of risk as a basis for deciding who to vacci-
nate is unlikely to be an effective approach [29]. Further,
most young women have not been infected with all vac-
cine-related HPV types and therefore can still achieve
some degree of protection through vaccination [16]. The
most effective way to protect the greatest number of
women against HPV infection is to optimize provision
of vaccine to all women eligible for vaccination [29].
Therefore, delivery of information to young women
about vaccine safety, vaccine efficacy, insurance cover-
age, and the value of vaccination to women in monoga-
mous relationships may be needed to better inform
those who decline HPV vaccination.
Additional material
Additional file 1: HPV vaccine questionnaire 18-26. This questionnaire
was directed toward 18-26 year old women and assessed HPV
vaccination status and reasons for vaccination/non-vaccination as well as
knowledge and attitudes about HPV and HPV vaccination.
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